Janice Kary

COO, Entanglement, Inc

Role: Associate

Site: CDL-Seattle

Stream: Computational Health

Janice Kary is Head of Business Operations and Chief of Staff at Clarion Cells, a Phase 2b clinical-stage biotechnology company developing CC-101, an off-the-shelf neural stem cell therapy designed to restore motor function in people living with chronic ischemic stroke. At Clarion, she leads finance, business operations and HR.

Janice brings more than two decades of experience across investment management, venture creation and company operations. Most recently, she served as Chief Operating Officer of Entanglement, Inc. and its spin-out seQure, where she oversaw finance, operations and human resources.

At Intellectual Ventures, Janice co-founded Kota Biotherapeutics, a B-cell engineering company, and helped spin out and raise capital for several of IV’s most successful startups. Earlier in her career, she built a long track record in finance and investment management in Asia and the United States, including at Morgan Stanley, Torrey Pines Capital Management and Headlands Capital Management.

Janice is a former board member of Modern Hydrogen and MedX Xelerator and a former board observer for Pivotal Commware. She also serves as a Mentor in the Computational Health stream at Creative Destruction Lab Seattle, mentoring early-stage science-based companies.

She holds an MBA from the UCLA Anderson School of Management and a BA from the University of British Columbia, where she majored in Chinese.